Basis: Latest reported fiscal quarter. Source: stored company filings and market data; unavailable inputs remain N/A.
The return on equity (ROE) is N/A as of the fiscal period ended Wednesday, December 31, 2025.
Trailing-twelve-month return on equity at each fiscal quarter end; no daily interpolation. Q4 FY2025 (2025-12-31): -471.37%.
RETURN ON EQUITY (ROE)
N/A
RETURN ON EQUITY (ROE) AVG TTM
-541.22%
RETURN ON EQUITY (ROE) AVG 3Y
-449.17%
RETURN ON EQUITY (ROE) AVG 5Y
-344.33%
RETURN ON EQUITY (ROE) AVG 10Y
-286.43%
RETURN ON EQUITY (ROE) AVG 15Y
N/A
RETURN ON EQUITY (ROE) AVG 20Y
N/A
CURRENT VS TTM AVG
N/A
CURRENT VS 3Y AVG
N/A
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
Dare Bioscience, Inc.
Market Cap
$12.54M
Return on Equity (ROE)
N/A
TTM Avg
-541.22%
3Y Avg
-449.17%
5Y Avg
-344.33%
Market Cap
$12.60M
Return on Equity (ROE)
N/A
TTM Avg
-162.71%
3Y Avg
-135.96%
5Y Avg
-98.83%
Market Cap
$12.63M
Return on Equity (ROE)
-97.47%
TTM Avg
-90.15%
3Y Avg
-205.18%
5Y Avg
-136.35%
Market Cap
$12.71M
Return on Equity (ROE)
N/A
TTM Avg
-180.04%
3Y Avg
-6461.50%
5Y Avg
-4315.55%
Market Cap
$12.91M
Return on Equity (ROE)
-74.73%
TTM Avg
-265.78%
3Y Avg
-138.63%
5Y Avg
-109.18%
Market Cap
$13.27M
Return on Equity (ROE)
-39.76%
TTM Avg
-59.76%
3Y Avg
-51.18%
5Y Avg
-40.48%
Market Cap
$11.69M
Return on Equity (ROE)
-37052.06%
TTM Avg
-237.80%
3Y Avg
-258.91%
5Y Avg
-310.30%
Market Cap
$12.92M
Return on Equity (ROE)
-810.41%
TTM Avg
-174.22%
3Y Avg
-126.94%
5Y Avg
-100.46%
Market Cap
$11.62M
Return on Equity (ROE)
-85.82%
TTM Avg
-222.53%
3Y Avg
-140.00%
5Y Avg
-73.12%
| NAME | MARKET CAP | RETURN ON EQUITY (ROE) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Dare Bioscience, Inc. (DARE) | $12.54M | N/A | -541.22% | -449.17% | -344.33% |
| Cytosorbents Corporation (CTSO)vs › | $12.60M | N/A | -162.71% | -135.96% | -98.83% |
| IRIDEX Corporation (IRIX)vs › | $12.63M | -97.47% | -90.15% | -205.18% | -136.35% |
| Lantern Pharma Inc. (LTRN)vs › | $12.71M | N/A | -180.04% | -6461.50% | -4315.55% |
| Cellectar Biosciences, Inc. (CLRB)vs › | $12.91M | -74.73% | -265.78% | -138.63% | -109.18% |
| Optimi Health Corp. (OPTH)vs › | $13.27M | -39.76% | -59.76% | -51.18% | -40.48% |
| Adial Pharmaceuticals, Inc. (ADIL)vs › | $11.69M | -37052.06% | -237.80% | -258.91% | -310.30% |
| Passage Bio, Inc. (PASG)vs › | $12.92M | -810.41% | -174.22% | -126.94% | -100.46% |
| Bullfrog AI Holdings, Inc. Common Stock (BFRG)vs › | $11.62M | -85.82% | -222.53% | -140.00% | -73.12% |
| Pluri Inc. (PLUR)vs › | $11.54M | N/A | 216.74% | -5384.23% | -3626.91% |
ROE
N/A
ROA
-49.1%
ROE = Net Income / Total Shareholders' Equity
Return on equity measures how efficiently a company generates profit from shareholders' equity. Higher ROE indicates better capital efficiency.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON EQUITY (ROE) |
|---|---|
| 2025-12-31 | -471.37% |
| 2025-09-30 | -611.08% |
| 2024-06-30 | -269.56% |
| 2023-03-31 | -615.33% |
| 2022-12-31 | -278.50% |
| 2022-09-30 | -93.18% |
| 2022-06-30 | -91.41% |
| 2022-03-31 | -128.80% |
| 2021-12-31 | -99.85% |
| 2021-09-30 | -117.90% |
| 2021-06-30 | -419.82% |
| 2021-03-31 | -935.24% |
| 2020-03-31 | -481.11% |
| 2019-09-30 | -735.58% |
| 2019-06-30 | -245.82% |
| 2019-03-31 | -320.74% |
| 2018-12-31 | -248.85% |
| 2018-09-30 | -239.50% |
| 2018-06-30 | -180.14% |
| 2018-03-31 | -142.61% |
| 2017-12-31 | -159.75% |
| 2017-09-30 | -76.02% |
| 2017-06-30 | -625.23% |
| 2017-03-31 | -414.70% |
| 2016-12-31 | -299.79% |
| 2016-09-30 | -271.18% |
| 2016-06-30 | -176.70% |
| 2016-03-31 | -124.25% |
| 2015-12-31 | -81.23% |
| 2015-09-30 | -61.99% |
| 2015-06-30 | -45.98% |
| 2015-03-31 | -71.41% |
| 2014-12-31 | -51.50% |
| 2014-09-30 | -36.84% |
| 2014-06-30 | -29.40% |
